A randomized controlled safety/efficacy trial of therapeutic vaccination in HIV-infected individuals who initiated antiretroviral therapy early in infection-Reference-Cited by-同舟云学术

A randomized controlled safety/efficacy trial of therapeutic vaccination in HIV-infected individuals who initiated antiretroviral therapy early in infection

Published:2017-12-06 Issue:419 Volume:9 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Sneller Michael C.¹^ORCID,Justement J. Shawn¹,Gittens Kathleen R.²,Petrone Mary E.¹,Clarridge Katherine E.¹^ORCID,Proschan Michael A.³^ORCID,Kwan Richard²,Shi Victoria¹,Blazkova Jana¹^ORCID,Refsland Eric W.¹^ORCID,Morris Daryl E.⁴^ORCID,Cohen Kristen W.⁴^ORCID,McElrath M. Juliana⁴⁵^ORCID,Xu Rong⁶^ORCID,Egan Michael A.⁶,Eldridge John H.⁶,Benko Erika⁷,Kovacs Colin⁷⁸,Moir Susan¹,Chun Tae-Wook¹^ORCID,Fauci Anthony S.¹

Affiliation:

1. Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD 20892, USA.

2. Critical Care Medicine Department, Clinical Center, NIH, Bethesda, MD 20892, USA.

3. Biostatistics Research Branch, NIAID, NIH, Bethesda, MD 20892, USA.

4. Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.

5. Department of Global Health, University of Washington, Seattle, WA 98195, USA.

6. Profectus BioSciences Inc., Tarrytown, NY 10591, USA.

7. Maple Leaf Medical Clinic, Toronto, Ontario M5G 1K2, Canada.

8. Department of Medicine, University of Toronto, Toronto, Ontario M5S 1A1, Canada.

Abstract

Despite lack of vaccine efficacy, the kinetics and magnitude of HIV rebound in early-treated patients affect future clinical trial design.

Funder

National Institutes of Health

NIH National Institute of Allergy and Infectious Diseases

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference36 articles.

1. Antiretroviral therapy and management of HIV infection

2. HIV reservoirs as obstacles and opportunities for an HIV cure

3. Therapeutic vaccines and immunological intervention in HIV infection

4. Safety and efficacy of the peptide-based therapeutic vaccine for HIV-1, Vacc-4×: a phase 2 randomised, double-blind, placebo-controlled trial

5. HIV-1 Tat B-cell epitope vaccination was ineffectual in preventing viral rebound after ART cessation

Cited by 103 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Definition of Virological Endpoints Improving the Design of Human Immunodeficiency Virus (HIV) Cure Strategies Using Analytical Antiretroviral Treatment Interruption;Clinical Infectious Diseases;2024-05-31

2. Inhibition of HIV-1 release by ADAM metalloproteinase inhibitors;Frontiers in Microbiology;2024-03-20

3. Impact of antiretroviral therapy during acute or early HIV infection on virologic and immunologic outcomes: results from a multinational clinical trial;AIDS;2024-03-13

4. Persistent HIV-1 transcription during ART: time to reassess its significance?;Current Opinion in HIV and AIDS;2024-03-12

5. Predictors of HIV rebound differ by timing of antiretroviral therapy initiation;JCI Insight;2024-02-08